Abacavir-induced fulminant hepatic failure in a HIV/HCV co-infected patient

BMJ Case Rep. 2015 Dec 15:2015:bcr2015212566. doi: 10.1136/bcr-2015-212566.

Abstract

Abacavir hypersensitivity is a rare, yet significant adverse reaction that results in a spectrum of physical and laboratory abnormalities, and has been postulated to stem from a variety of aetiological factors. The major histocompatibility complex haplotype human leucocyte antigen (HLA)-B5701 is a significant risk factor in development of hypersensitivity reactions, yet only 55% of HLA-B5701+ individuals develop such reactions, suggesting a multifactorial aetiology. Nevertheless, prospective screening and avoidance of abacavir in these patients has limited adverse events. Within this spectrum of adverse events, abacavir-induced liver toxicity is exceedingly rare and reported events have ranged from mild elevations of aminotransferases to fulminant hepatic failure. We report the case of a 50-year-old Caucasian woman with a history significant for HIV, hepatitis C virus and a HLA-B5701+ status, transferred to our emergency department in a hypotensive state and found to have acute liver failure, acute renal failure and significant rhabdomyolysis following a change of highly active antiretroviral therapy regimen.

Publication types

  • Case Reports

MeSH terms

  • Anti-HIV Agents / adverse effects*
  • Antiretroviral Therapy, Highly Active / adverse effects
  • Coinfection
  • Dideoxynucleosides / adverse effects*
  • Female
  • HIV Infections / complications*
  • HIV Infections / drug therapy*
  • HIV Infections / immunology
  • HLA-B Antigens
  • Hepatitis C / complications*
  • Hepatitis C / immunology
  • Humans
  • Liver Failure, Acute / chemically induced*
  • Liver Failure, Acute / immunology
  • Middle Aged
  • Prospective Studies
  • Risk Factors

Substances

  • Anti-HIV Agents
  • Dideoxynucleosides
  • HLA-B Antigens
  • HLA-B*57:01 antigen
  • abacavir